5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.25▲ | 1.26▼ | 1.26▼ | 1.26▼ | 1.42▼ |
MA10 | 1.25▲ | 1.25▲ | 1.25▲ | 1.33▼ | 1.35▼ |
MA20 | 1.26▼ | 1.26▼ | 1.26▼ | 1.42▼ | 1.21▲ |
MA50 | 1.28▼ | 1.34▼ | 1.34▼ | 1.34▼ | 1.21▲ |
MA100 | 1.38▼ | 1.45▼ | 1.46▼ | 1.20▲ | 1.28▼ |
MA200 | 1.48▼ | 1.41▼ | 1.36▼ | 1.21▲ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.003▲ | 0.006▲ | 0.007▲ | -0.031▼ | 0.018▲ |
RSI | 46.594▼ | 41.663▼ | 40.934▼ | 39.020▼ | 49.669▼ |
STOCH | 35.317 | 54.167 | 54.167 | 16.450▼ | 51.253 |
WILL %R | -57.143 | -44.444 | -44.444 | -88.095▼ | -68.750 |
CCI | 5.352 | -15.025 | -15.025 | -99.993 | -11.584 |
CDL | $VANI Doji Candlestick Pattern Detected | Set Alert |
Thursday, August 14, 2025 09:11 AM
Vivani Medical (Nasdaq:VANI) announced that it brought in $10 million in equity financing as it progresses its drug delivery technology.
|
Thursday, August 14, 2025 02:23 AM
Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...
|
Wednesday, August 13, 2025 01:29 PM
Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 1.25 | 1.27 | 1.23 | 1.25 | 96,681 |
14/08/25 | 1.24 | 1.28 | 1.225 | 1.27 | 61,842 |
13/08/25 | 1.26 | 1.28 | 1.25 | 1.26 | 65,600 |
12/08/25 | 1.25 | 1.28 | 1.20 | 1.27 | 100,400 |
11/08/25 | 1.38 | 1.38 | 1.26 | 1.26 | 140,000 |
08/08/25 | 1.37 | 1.39 | 1.37 | 1.38 | 34,869 |
07/08/25 | 1.42 | 1.445 | 1.35 | 1.36 | 133,000 |
06/08/25 | 1.45 | 1.4796 | 1.38 | 1.39 | 134,762 |
05/08/25 | 1.36 | 1.55 | 1.33 | 1.50 | 1,422,102 |
04/08/25 | 1.33 | 1.41 | 1.30 | 1.40 | 81,282 |
|
|
||||
|
|
||||
|
|